Genmab — Maj 2021
-
God morgen
-
God morgen.
-
Luk i USA i går: Dow Jones steg 0,92 procent Nasdaq op 0,37 procent S&P 500 op 0,81 procent NBI i minus 0,31 procent.
-
Asien: Stigninger på baggrund af stor optimisme inden jobrapport
https://www.proinvestor.com/investornyt/674853/asien-stigninger-pa-baggrund-af-stor-optimisme-inden-jobrapport -
Fredagens aviser med Genmab, GN og Netcompany: https://www.proinvestor.com/investornyt/674852/fredagens-aviser-med-genmab-gn-og-netcompany
-
Hvis du rammer den igen i dag - forventer jeg "PI hatten" bliver sendt rundt. Held og lykke
-
Aktier/tendens: Masser af kursmål-justeringer oven i et par regnskaber https://www.proinvestor.com/investornyt/674866/aktier-tendens-masser-af-kursmal-justeringer-oven-i-et-par-regnskaber
-
ADC Therapeutics Reports Camidanlumab Tesirine (Cami)
Ongoing trials progressing:
The pivotal Phase 2 clinical trial evaluating the efficacy and safety of Cami in patients with relapsed or refractory Hodgkin lymphoma (HL) has completed enrollment and is continuing to follow patients. The Company will present data from this study at an upcoming congress. -
The Phase 1b clinical trial of Cami in combination with pembrolizumab in selected advanced solid tumors is an open-label, dose-escalation and dose-expansion trial evaluating the safety, tolerability, pharmacokinetics and antitumor activity of Cami in combination with pembrolizumab, a checkpoint inhibitor.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind